Global pharma giant Novartis, has struck a deal with UK government to supply late-stage cholesterol drug to patients with high-risk of heart attack. The drug will be administered to patients with Atherosclerosis, a heart disease in which plaque builds up inside arteries, and can lead to heart attack, stroke or death.

The drug, which is pending approval in USA, will be provided on population basis, once it is tested in a large clinical trial and approved for use there. The drug called Inclisiran, targets protein that is involved in producing LDL, or bad cholesterol. The drug is intended to be used in addition to statins for patients who struggle to lower cholesterol with traditional therapy.